For example, Ikeda et al. [89] evaluated 14 patients using a commercial NGS panel and showed that advanced HCC patients with PTEN-inactivating and MET-activating mutations can benefit from therapy with sirolimus and cabozantinib, which are inhibitors of the relevant pathways. Here, PTEN is linked to hepatocellular carcinoma.